Aphios Pharma
OperatingAphios Pharma LLC
Software & AI · Founded 2018
Aphios Pharma LLC, a wholly-owned subsidiary of Aphios Corporation, is dedicated to the discovery, delivery, development and commercialization of drugs to treat Central Nervous System (CNS) and other disorders with a focus on Opioid Addiction.
Financials
FY2016–FY2025 · from SEC filings · hover any figure for its sourceChart shows the most recent 8 fiscal years; 2 earlier years are in the table below.
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher. Dashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth, so don't compare them with the other bars.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Share counts as of Dec 31, 2023| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Membership Units | 20,046,502 | — | 100.0% | $3.44Oct 2024 |
Sold to the crowd
- Reg CF · Sep 201848,152 shares at $1.00$48.2K
- Reg CF · Oct 2021$97K· 88 investors
- Reg CF · Oct 202418,893 shares at $3.44$65K
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
1 personNames and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 6 of 8 annual reports (FY2018–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 21 filings on EDGAR- Form C-UMay 6, 20260001669191-26-000173EDGAR
- Form C-ARApr 1, 20260001750795-26-000002EDGAR
- Form C/AJul 10, 20250001669191-25-000418EDGAR
- Form C/AJul 1, 20250001669191-25-000403EDGAR
- Form C/AApr 15, 20250001669191-25-000264EDGAR
- Form C/AApr 4, 20250001669191-25-000249EDGAR
- Form C/AMar 31, 20250001669191-25-000222EDGAR
- Form C/AJan 31, 20250001669191-25-000055EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.